abstract: The objective of this study was to determine the effect of different levels of dietary @entity2 on selected immune parameters of young @entity0 . A total of 357 one-day-old female Hybrid Converter @entity0 were randomly divided into three groups with low, medium and high level of dietary me- @entity3 (LM, MM, HM) of seven replicates each. @entity2 was added to the basal diet (LM) at 0.16% (MM) and 0.32% (HM). At 17 days of age, seven birds per group were vaccinated against @entity1 , with ORNITIN (ABIC) vaccine. At 28 days of age, blood was sampled and the birds were euthanized. The serum concentrations and activity of selected biochemical parameters, total IgY and IgM, and vaccine-induced antibody titers (IgY) against ORT were determined. The percentages of @entity4 +, @entity5 +, @entity4 +/ @entity5 + T cell subpopulations and IgM+ B cell subpopulation were determined in blood and organs by flow cytometry. Different supplementary levels of @entity2 had no significant effect on vaccine-induced anti- body titers against ORT or total serum IgM and IgY levels, as well as on the percentages of periph- eral blood T and B cell subsets. Increasing dietary @entity2 rates decreased the percentage of @entity4 + T cell subpopulation, however it has increased the percentage of IgM+ B cell subpopulation in the spleen. Vaccination against ORT resulted in a significant decrease in the percentage of @entity4 + T cell subset and an increase in the percentage of @entity5 + T cell subset in the spleen. It could be concluded that MM @entity0 have developed the most desirable values of immune parameters.

title: Immunological and biochemical indicators in @entity0 fed diets with a different XXXX content.

answer: @entity2


abstract: OBJECTIVE: To investigate the feasibility and short-term effectiveness of percutaneous endoscopic spine surgery for treatment of @entity5 with posterior ring apophysis separation. METHODS: Between July 2008 and January 2013, 57 @entity0 with @entity5 and posterior ring apophysis separation were treated. There were 39 males and 18 females, aged from 13 to 46 years (mean, 26.7 years). Of 57 cases, 29 had a clear @entity1 history. All @entity0 had @entity5 , and the location was at L4, 5 in 22 cases and at L5, S1 in 35 cases; there were 25 cases of lateral bone fragments and 32 cases of central cortical and cancellous fragments. While @entity2 located at posterior inferior edge of the vertebrae at L4 level in 9 cases and at Ls level in 8 cases, at posterior superior edge at L5 level in 13 cases and in S1 level in 27 cases. Percutaneous endoscopic surgeries were performed via interlaminar or transforaminal approach from unilaterally symptomatic side for discectomy of @entity5 and partial or complete resection of free bone fragments. RESULTS: Accurate positioning was obtained in all @entity0 during operation, and no complication of nerve @entity1 , @entity6 formation, or dural tear occurred. The operation time was 20-85 minutes; the intraoperative fluoroscopy times were 2-15 times, and the @entity3 was 3-10 mL. Postoperative radiographic examination showed that bone fragment was not removed in 16 cases, was partly removed in 32 cases, and was completely removed in 9 cases. Disc was completely removed. All @entity0 were followed up 10-64 months (median, 16 months). According to modified Macnab criteria for the evaluation of effectiveness, the results were excellent in 48 cases, good in 6 cases, and fair in 3 cases, and the excellent and good rate was 94.7%. CONCLUSION: Percutaneous endoscopic spine surgery through unilaterally symptomatic approach has advantages of small tissue damage and lumbar structure damage, less @entity4 , and shorter recovery time. It has a good short-term effectiveness, but long-term effectiveness need further follow-up.

title: [Short-term effectiveness of percutaneous endoscopic spine surgery for treatment of XXXX with posterior ring apophysis separation].

answer: @entity5


abstract: UNASSIGNED: Ganoderma lucidum, a hallmark of traditional Chinese medicine, has been widely used as a pharmacologically active compound. Although numerous research studies have focused on the pharmacological mechanism, fewer studies have explored the basic biological features of this species, restricting the further development and application of this important mushroom. Because of the ability of this mushroom to reduce and detoxify the compounds produced by various metabolic pathways, @entity1 peroxidase (GPx) is one of the most important antioxidant enzymes with respect to ROS. Although studies in both animals and plants have suggested many important physiological functions of GPx, there are few systematic research studies concerning the role of this enzyme in fungi, particularly in large basidiomycetes. In the present study, we cloned the GPx gene and created GPx-silenced strains by the down-regulation of GPx gene expression using RNA interference. The results indicated an essential role for GPx in controlling the intracellular @entity2 content, hyphal branching, antioxidant stress tolerance, cytosolic @entity0 content and @entity3 biosynthesis. Further mechanistic investigation revealed that GPx is regulated by intracellular @entity2 levels and suggested that crosstalk occurs between GPx and intracellular @entity2 . Moreover, evidence was obtained indicating that GPx regulation of hyphal branching via ROS might occur independently of the cytosolic @entity0 content. Further mechanistic investigation also revealed that the effects of GPx on @entity3 synthesis via ROS are regulated by the cytosolic @entity0 content. Taken together, these findings indicate that ROS have a complex influence on growth, development and secondary metabolism in fungi and that GPx serves an important function. The present study provides an excellent framework to identify GPx functions and highlights a role for this enzyme in ROS regulation.

title: Functional analysis of the role of @entity1 peroxidase (GPx) in the ROS signaling pathway, hyphal branching and the regulation of XXXX biosynthesis in Ganoderma lucidum.

answer: @entity3


abstract: UNASSIGNED: Ganoderma lucidum, a hallmark of traditional Chinese medicine, has been widely used as a pharmacologically active compound. Although numerous research studies have focused on the pharmacological mechanism, fewer studies have explored the basic biological features of this species, restricting the further development and application of this important mushroom. Because of the ability of this mushroom to reduce and detoxify the compounds produced by various metabolic pathways, @entity1 peroxidase (GPx) is one of the most important antioxidant enzymes with respect to ROS. Although studies in both animals and plants have suggested many important physiological functions of GPx, there are few systematic research studies concerning the role of this enzyme in fungi, particularly in large basidiomycetes. In the present study, we cloned the GPx gene and created GPx-silenced strains by the down-regulation of GPx gene expression using RNA interference. The results indicated an essential role for GPx in controlling the intracellular @entity2 content, hyphal branching, antioxidant stress tolerance, cytosolic @entity0 content and @entity3 biosynthesis. Further mechanistic investigation revealed that GPx is regulated by intracellular @entity2 levels and suggested that crosstalk occurs between GPx and intracellular @entity2 . Moreover, evidence was obtained indicating that GPx regulation of hyphal branching via ROS might occur independently of the cytosolic @entity0 content. Further mechanistic investigation also revealed that the effects of GPx on @entity3 synthesis via ROS are regulated by the cytosolic @entity0 content. Taken together, these findings indicate that ROS have a complex influence on growth, development and secondary metabolism in fungi and that GPx serves an important function. The present study provides an excellent framework to identify GPx functions and highlights a role for this enzyme in ROS regulation.

title: Functional analysis of the role of XXXX peroxidase (GPx) in the ROS signaling pathway, hyphal branching and the regulation of @entity3 biosynthesis in Ganoderma lucidum.

answer: @entity1


abstract: UNASSIGNED: Objective   The timely detection of @entity1 can be critical for the survival of a neurosurgical @entity0 following @entity4 . Because little reliable evidence is available on the prognostic value of the clinical sign "extensor response" in @entity5 posttraumatic @entity0 , we investigated the correlation of this clinical sign with outcome and with early radiologic findings from magnetic resonance imaging (MRI). Methods   This retrospective analysis of prospectively obtained data included 157 @entity0 who had remained in a @entity5 for a minimum of 24 hours after @entity3 . All @entity0 received a 1.5-T MRI within 10 days (median: 2 days) of the injury. The correlations between clinical findings 12 and 24 hours after the injury-in particular, extensor response and pupillary function, MRI findings, and outcome after 1 year-were investigated. Statistical analysis included contingency tables, Fisher exact test, odds ratios (ORs) with confidence intervals (CIs), and weighted k values. Results   There were 48 @entity0 with extensor response within the first 24 hours after the injury. @entity0 with extensor response (World Federation of Neurosurgical Societies @entity5 grade III) statistically were significantly more likely to @entity2 in the brainstem when compared with @entity0 in a @entity5 who had no further deficiencies ( @entity5 grade I; p   =   0.0004 by Fisher exact test, OR 10.8 with 95% CI, 2.7-42.5) and @entity0 with unilateral loss of pupil function ( @entity5 grade II; p   =   0.0187, OR 2.8 with 95% CI, 1.2-6.5). The correlation of @entity2 as found by MRI and outcome according to the Glasgow Outcome Scale after 1   year was also highly significant (p    <=   0.016). Conclusion   The correlation of extensor response and loss of pupil function with an unfavorable outcome and with @entity2 revealed by MRI is highly significant. Their sudden onset may be associated with the @entity6 and should therefore be regarded as one of the most fundamental warning signs in the clinical monitoring of @entity5 @entity0 .

title: Clinical, Radiologic, and Legal Significance of "Extensor Response" in XXXX .

answer: @entity5


abstract: BACKGROUND: Severe haemolysis is a rare complication after mitral valve repair in @entity1 . AIM: We describe four @entity0 with severe @entity2 who underwent valve repair and subsequently developed profound @entity3 . METHODS: Clinical, echocardiographic and surgical data were collected retrospectively from a surgical centre in France during a 5-year period. RESULTS: Two @entity0 had @entity4 , one @entity0 had @entity2 and one had anomalous left coronary artery from the pulmonary artery with @entity2 . Haemolysis was diagnosed 20 to 75days after surgery, as a result of clinical and biological examination; it was severe, and blood transfusion support was necessary in all cases. Haemolysis was always associated with eccentric @entity2 with a variable degree of severity (from low to severe). After exclusion of other haemolysis aetiology, redo mitral repair surgery was performed successfully in all cases. The haemolysis was considered to be mechanical in origin, caused by regurgitation of blood through the residual @entity2 and stitches. CONCLUSION: Severe haemolysis is a rare complication that can occur after mitral valve repair in @entity1 . All @entity0 underwent successful redo repair and had resolution of haemolysis after surgery. Even if redo surgery is required, iterative mitral repair is possible.

title: Repeat mitral valve repair for haemolysis in XXXX .

answer: @entity0


abstract: The concept of @entity8 is defined by a group of clinical and electrocardiographic features related to @entity8 whatever its mechanism; the organicity of the disease can be proven if total or subtotal histological alterations of the sinus node are demonstrated. The most typical symptoms are neurological ( @entity5 and @entity7 ). @entity9 , sinus @entity6 or @entity6 , and the @entity6 - @entity3 syndrome are the most usual electrocardiographic aspects. The diagnosis is often rendered difficult by the usually intermittent and frequently nonspecific character of the symptoms and of the ECG signs. Holter monitoring is often essential to resolve these difficulties. If the diagnosis remains dubious, the use of electrophysiological methods is necessary: direct recording of the sinus nodal intracardiac potential can now be added to the classical rapid and premature atrial stimulation, possibly complemented by pharmacological tests. Finally, therapeutic indications can be considered after a correct clinical, electrocardiographical and electrophysiological evaluation of the @entity0 . Medical treatment alone is usually ineffective in controlling the attacks of @entity4 and the @entity1 . If the sinus @entity2 is obvious and symptomatic, permanent pacing is the treatment of choice. Its short and medium term results are generally excellent, while the long term results, especially with regard to survival of the @entity0 , could be improved by the most recent pacing techniques.

title: [ XXXX - diagnosis and treatment].

answer: @entity8


abstract: PURPOSE: To compare the subfoveal, parafoveal, and peripapillary @entity1 with those of fellow and control eyes. METHODS: This institutional study involved 114 eyes from 38 @entity0 with unilateral @entity3 and 19 healthy @entity0 , aged 6 to 17 years. The cause of @entity3 was identified as hyperopic @entity4 in 17 cases and strabismus in 21 cases. All @entity0 underwent central macular thickness (CMT) and @entity2 at seven retinal sites with spectral-domain optical coherence tomography (OCT). Statistical analysis was performed to compare the CMT and @entity1 with control eyes. RESULTS: Average CMT was 248.31    24.18  m in amblyopic eyes, 249.76    26.08  m in fellow eyes, and 243.65    31.96  m in controls (P = .604). Average subfoveal choroidal thickness was 394.15    71.03  m in amblyopic eyes, 356.07    79.93  m in fellow eyes, and 319.44    87.29  m in controls (P = .000). The choroidal thickness of the subfoveal area and at 750- m intervals temporal and nasal to the fovea was significantly thicker in amblyopic eyes than in controls (P < .05). The choroidal thickness was significantly thicker in amblyopic eyes than in fellow eyes only at 750  m nasal to the fovea. Type and depth of @entity3 did not differ significantly between foveal or parafoveal choroidal thickness (P > .05). There was a significant negative correlation between the nasal peripapillary choroidal thickness and the axial length in the amblyopic eyes (r = -0.37, P = .022). The choroidal thickness in the peripapillary area was not significantly different in the three groups (P > .05). CONCLUSIONS: This study demonstrated that choroidal thickness can be measured by spectral-domain OCT in @entity0 with @entity3 . Subfoveal @entity1 was significantly thicker than in control eyes. The amblyopic process may involve the choroid, but not the macula. However, further evaluation is needed.

title: Analysis of Choroidal Thickness Using Spectral-Domain OCT in XXXX With Unilateral Amblyopia.

answer: @entity0


abstract: OBJECTIVES: To analyze margin status and prognostic factors for complications in @entity0 undergoing vulvectomy for invasive @entity2 (iSCC) with and without plastic-assisted closure. METHODS: Demographic and clinical data were collected on 94 @entity0 with iSCC who underwent vulvectomy between 2004 and 2013. All pathology slides were re-reviewed by two gynecologic pathologists. Data were analyzed using XLSTAT-Pro v2014.2.02. RESULTS: Of 88 eligible @entity0 , 15 (17%) had plastic-assisted vulvar closure and 73 (83%) did not. There were significantly more @entity0 in the plastics group with recurrent disease (53% v 10%) and history radiation therapy prior to surgery (40% versus 5%). Plastic-assisted closure was associated with larger @entity1 (3.73cm versus 2.03cm, p<0.01) and a higher frequency of adequate margins (53% versus 29%, p=0.06). For @entity1 >= 3.0cm, plastic-assisted closure was significantly associated with adequate margins (44% versus 6%, p=0.03). Prior radiation use was associated with plastic-assisted closure, larger @entity1 , older age, and recurrent disease. Complications occurred in 36 @entity0 (41%) and significantly more occurred in those with plastic-assisted closure (67% versus 36%, p=0.04). On multivariate analysis including age, @entity1 size, recurrent disease, plastic-assisted closure, and history of radiation, only history of radiation therapy was a significant predictor of complications (OR=17, 95%CI 2.05-141.35; p=0.01). CONCLUSIONS: Plastic-assisted vulvectomy closure was more often utilized in cases involving @entity1 . Plastic-assisted closure significantly increased the frequency of adequate margins in @entity1 >= 3cm and did not impact complications.

title: Does plastic surgical consultation improve the outcome of XXXX undergoing radical vulvectomy for squamous cell carcinoma of the vulva?

answer: @entity0


abstract: AIMS: This study is to investigate the effect of amyloid b1-42 oligomers on insulin signaling in astrocytes. METHODS: Synthetic Ab1-42 oligomers were prepared and the oligomeric form of Ab1-42 was verified by an electron microscope. Normal @entity0 astrocytes were cultured in Dulbecco's Modified Eagle Medium. Western blotting was employed to measure the amount of lysate proteins. Immunofluorescence was performed to detect the distribution of phosphorylated @entity4 and expression of P- @entity3 in astrocytes under confocal microscopy and fluorescent microscopy, respectively. Periodic Acid-Schiff staining was used to detect glycogen, the content of which was measured using glycogen assay. RESULTS: Our data showed that Ab1-42 oligomers inhibited insulin-induced serine phosphorylation of Akt at 473 and @entity3 at serine 9, as well as glycogen storage. However, the levels of phosphorylated @entity3 at tyrosine 216 were significantly increased in the presence of Ab1-42 oligomers. In addition, the levels of phosphorylated @entity1 and @entity4 at serine 636/639 were significantly increased in response to treatment with Ab1-42 oligomers. Of note, the responses and inhibitory effects of Ab1-42 oligomers on insulin signaling were partially reversed by @entity1 upstream inhibitor @entity2 . CONCLUSIONS: Our results demonstrated that Ab1-42 oligomers impaired insulin signaling and suppressed insulin-induced glycogen storage in @entity0 astrocytes, probably due to @entity1 -dependent serine phosphorylation of @entity4 at 636/639 induced by Ab1-42 oligomers.

title: Amyloid b oligomer-induced XXXX -dependent serine 636/639 phosphorylation of @entity4 impairs insulin signaling and glycogen storage in @entity0 astrocytes.

answer: @entity1


abstract: AIMS: This study is to investigate the effect of amyloid b1-42 oligomers on insulin signaling in astrocytes. METHODS: Synthetic Ab1-42 oligomers were prepared and the oligomeric form of Ab1-42 was verified by an electron microscope. Normal @entity0 astrocytes were cultured in Dulbecco's Modified Eagle Medium. Western blotting was employed to measure the amount of lysate proteins. Immunofluorescence was performed to detect the distribution of phosphorylated @entity4 and expression of P- @entity3 in astrocytes under confocal microscopy and fluorescent microscopy, respectively. Periodic Acid-Schiff staining was used to detect glycogen, the content of which was measured using glycogen assay. RESULTS: Our data showed that Ab1-42 oligomers inhibited insulin-induced serine phosphorylation of Akt at 473 and @entity3 at serine 9, as well as glycogen storage. However, the levels of phosphorylated @entity3 at tyrosine 216 were significantly increased in the presence of Ab1-42 oligomers. In addition, the levels of phosphorylated @entity1 and @entity4 at serine 636/639 were significantly increased in response to treatment with Ab1-42 oligomers. Of note, the responses and inhibitory effects of Ab1-42 oligomers on insulin signaling were partially reversed by @entity1 upstream inhibitor @entity2 . CONCLUSIONS: Our results demonstrated that Ab1-42 oligomers impaired insulin signaling and suppressed insulin-induced glycogen storage in @entity0 astrocytes, probably due to @entity1 -dependent serine phosphorylation of @entity4 at 636/639 induced by Ab1-42 oligomers.

title: Amyloid b oligomer-induced @entity1 -dependent serine 636/639 phosphorylation of XXXX impairs insulin signaling and glycogen storage in @entity0 astrocytes.

answer: @entity4


abstract: AIMS: This study is to investigate the effect of amyloid b1-42 oligomers on insulin signaling in astrocytes. METHODS: Synthetic Ab1-42 oligomers were prepared and the oligomeric form of Ab1-42 was verified by an electron microscope. Normal @entity0 astrocytes were cultured in Dulbecco's Modified Eagle Medium. Western blotting was employed to measure the amount of lysate proteins. Immunofluorescence was performed to detect the distribution of phosphorylated @entity4 and expression of P- @entity3 in astrocytes under confocal microscopy and fluorescent microscopy, respectively. Periodic Acid-Schiff staining was used to detect glycogen, the content of which was measured using glycogen assay. RESULTS: Our data showed that Ab1-42 oligomers inhibited insulin-induced serine phosphorylation of Akt at 473 and @entity3 at serine 9, as well as glycogen storage. However, the levels of phosphorylated @entity3 at tyrosine 216 were significantly increased in the presence of Ab1-42 oligomers. In addition, the levels of phosphorylated @entity1 and @entity4 at serine 636/639 were significantly increased in response to treatment with Ab1-42 oligomers. Of note, the responses and inhibitory effects of Ab1-42 oligomers on insulin signaling were partially reversed by @entity1 upstream inhibitor @entity2 . CONCLUSIONS: Our results demonstrated that Ab1-42 oligomers impaired insulin signaling and suppressed insulin-induced glycogen storage in @entity0 astrocytes, probably due to @entity1 -dependent serine phosphorylation of @entity4 at 636/639 induced by Ab1-42 oligomers.

title: Amyloid b oligomer-induced @entity1 -dependent serine 636/639 phosphorylation of @entity4 impairs insulin signaling and glycogen storage in XXXX astrocytes.

answer: @entity0


abstract: INTRODUCTION: Recurrent @entity1 is common, costly, and lethal, yet we know little about it in community-based populations. Electronic health records and @entity1 registries contain vast amounts of data regarding community-based @entity0 , but usually lack recurrence status. Existing algorithms that use structured data to detect recurrence have limitations. METHODS: We developed algorithms to detect the presence and timing of recurrence after definitive therapy for stages I-III lung and @entity2 using 2 data sources that contain a widely available type of structured data (claims or electronic health record encounters) linked to gold-standard recurrence status: Medicare claims linked to the @entity1 Care Outcomes Research and Surveillance study, and the @entity1 Research Network Virtual Data Warehouse linked to registry data. Twelve potential indicators of recurrence were used to develop separate models for each @entity1 in each data source. Detection models maximized area under the ROC curve (AUC); timing models minimized average absolute error. Algorithms were compared by @entity1 type/data source, and contrasted with an existing binary detection rule. RESULTS: Detection model AUCs (>0.92) exceeded existing prediction rules. Timing models yielded absolute prediction errors that were small relative to follow-up time (<15%). Similar covariates were included in all detection and timing algorithms, though differences by @entity1 type and dataset challenged efforts to create 1 common algorithm for all scenarios. CONCLUSIONS: Valid and reliable detection of recurrence using big data is feasible. These tools will enable extensive, novel research on quality, effectiveness, and outcomes for lung and @entity2 @entity0 and those who develop recurrence.

title: Detecting Lung and XXXX Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management.

answer: @entity2


abstract: BACKGROUND: @entity3 ( @entity3 ) is the third most common @entity2 . The efficacy of surgical treatment of neglected @entity3 after skeletal maturity in adults remains controversial. The aim of this retrospective study was to determine the efficacy of arthroscopic release of the sternocleidomastoid (SCM) muscle for the treatment of neglected @entity3 in adult cases. METHODS: From April 2008 to July 2013, a total of 20 adult @entity0 (9 @entity0 and 11 @entity0 ) with a mean age of 23.0 years were surgically treated for neglected @entity3 with local anesthesia. The SCM muscle and clavicle were preoperatively marked. Through an artificial lacuna, an arthroscope and a radiofrequency probe were inserted. The sternal and clavicular attachments were dissected and divided via radiofrequency. Clinical evaluation was assessed using a modified Cheng and Tang score. RESULTS: The operation was successfully completed in all the @entity0 . Follow-up examinations from 12 to 40 months in the 20 @entity0 showed complete muscular release and satisfactory cosmetic appearance with no recurrence. There was no evidence of serious complications. The neck scars were no longer visible after several weeks. According to the modified Cheng and Tang scale, 11 @entity0 displayed an excellent result and 9 @entity0 had a good result. CONCLUSIONS: Arthroscopic release of the SCM muscle with local anesthesia is a simple and effective way to surgically manage neglected @entity3 without any risk for either @entity1 or leaving visible scars.

title: Arthroscopic Surgical Treatment for Neglected XXXX in Adults.

answer: @entity3


abstract: UNASSIGNED: Higher serum level of @entity3 (PC) in @entity4 ( @entity4 ) @entity0 has been linked with @entity4 progression. The toxic effect of PC on diverse cells has been reported by prior studies, except for renal tubular cells. Both autophagy and apoptosis contribute to renal tubular cell death, yet evidence of its response to PC is limited and their crosstalk is still unclear. Autophagy is an important cellular process involved in toxin-induced cell death. @entity1 in @entity5 is thought to be one of the key events causing the progression of @entity4 . Thus, we treated @entity2 (NRK-52E) and @entity0 (HRPTEC) renal proximal tubular cells (RPTC) with PC and found the cell proliferation was significantly decreased. Cell apoptosis was significantly increased and accompanied with the activation of autophagy as evidenced by increases in LC3-II, @entity8 and Atg 4. We also found an increase of @entity9 by @entity6 activation. @entity9 accumulation could mediate the activation of @entity7 -dependent cell apoptosis. Conversely, knockdown of @entity9 by siRNA of @entity9 had the opposite effect by arresting LC3-II accumulation and promoting increasing cell viability. We conclude that PC triggered autophagic RPTC death via JNK-mediated @entity9 accumulation and then activated @entity7 -dependent cell death pathway. PC can be considered as one of the key events causing progression of @entity4 , which might affect drug disposition in @entity4 cases.

title: XXXX mediates autophagic cell death in renal proximal tubular cells.

answer: @entity3


abstract: STUDY DESIGN.: Retrospective analysis of a prospectively collected single-center database. OBJECTIVE.: We describe a modified halo-gravity traction (HGT) protocol for @entity0 with severe @entity2 in @entity4 , and assess the clinical and radiographic outcomes. SUMMARY OF BACKGROUND DATA.: Three-column osteotomies are frequently used in the correction of severe @entity2 ; however, these can be associated with high complication rates and significant risk for @entity1 . Preoperative traction is one modality used to obtain a partial correction prior to definitive fusion. Low numbers and variability of traction protocols, however, have limited previous reports of sustained HGT. METHODS.: All @entity0 who underwent HGT in Ghana from April 2012 to August 2013 were reviewed. HGT was started at 20% body weight and increased by 10% per week until 50% body weight was reached by 4 weeks or thereafter as tolerated. Demographic variables, operative data, radiographic parameters, and health-related quality of life scores were collected. @entity2 reduction index was calculated at each time point by summing the scoliosis and abnormal @entity5 for each @entity0 and reported as a percentage of the @entity2 . RESULTS.: Twenty-nine @entity0 underwent HGT for an average 107 days prior to definitive posterior spinal fusion (24 @entity0 ) or placement of growing rods (5 @entity0 ). The major curve improved from an average 131   to 90   (31%) after HGT, and to an average 57   (56%) postoperatively. Pure kyphotic curves were rigid (flexibility 22% after traction), with a correction index of 3.88, which is similar to historical controls. @entity2 with HGT plateaued at 63 days. Overall Scoliosis Research Society-22 questionnaire scores improved significantly pretraction versus postoperatively, but there was no change after traction versus before traction. There were 11 pin tract infections, with no @entity1 . CONCLUSION.: HGT is a safe method to partially correct severe @entity2 prior to a definitive procedure, and may reduce the need for higher risk 3-column osteotomies. Importantly, @entity5 secondary to infection with spontaneous @entity3 is relatively resistant to HGT.Level of Evidence: 4.

title: Preoperative Halo-Gravity Traction for Severe XXXX at an SRS-GOP Site in @entity4 : Protocols, Complications, and Results.

answer: @entity2


abstract: STUDY DESIGN.: Retrospective analysis of a prospectively collected single-center database. OBJECTIVE.: We describe a modified halo-gravity traction (HGT) protocol for @entity0 with severe @entity2 in @entity4 , and assess the clinical and radiographic outcomes. SUMMARY OF BACKGROUND DATA.: Three-column osteotomies are frequently used in the correction of severe @entity2 ; however, these can be associated with high complication rates and significant risk for @entity1 . Preoperative traction is one modality used to obtain a partial correction prior to definitive fusion. Low numbers and variability of traction protocols, however, have limited previous reports of sustained HGT. METHODS.: All @entity0 who underwent HGT in Ghana from April 2012 to August 2013 were reviewed. HGT was started at 20% body weight and increased by 10% per week until 50% body weight was reached by 4 weeks or thereafter as tolerated. Demographic variables, operative data, radiographic parameters, and health-related quality of life scores were collected. @entity2 reduction index was calculated at each time point by summing the scoliosis and abnormal @entity5 for each @entity0 and reported as a percentage of the @entity2 . RESULTS.: Twenty-nine @entity0 underwent HGT for an average 107 days prior to definitive posterior spinal fusion (24 @entity0 ) or placement of growing rods (5 @entity0 ). The major curve improved from an average 131   to 90   (31%) after HGT, and to an average 57   (56%) postoperatively. Pure kyphotic curves were rigid (flexibility 22% after traction), with a correction index of 3.88, which is similar to historical controls. @entity2 with HGT plateaued at 63 days. Overall Scoliosis Research Society-22 questionnaire scores improved significantly pretraction versus postoperatively, but there was no change after traction versus before traction. There were 11 pin tract infections, with no @entity1 . CONCLUSION.: HGT is a safe method to partially correct severe @entity2 prior to a definitive procedure, and may reduce the need for higher risk 3-column osteotomies. Importantly, @entity5 secondary to infection with spontaneous @entity3 is relatively resistant to HGT.Level of Evidence: 4.

title: Preoperative Halo-Gravity Traction for Severe @entity2 at an SRS-GOP Site in XXXX : Protocols, Complications, and Results.

answer: @entity4


abstract: @entity2 ( @entity2 ) is, in the great majority of cases, a neoplastic proliferation of B cells. The associated immunologic dysfunction accounts for many of the clinically associated phenomenon such as @entity1 and second @entity0 . Much of this dysfunction has been attributed to poor B-cell function. Functional impairment of the T-cell component is currently being elucidated. In the investigation of B cells. The associated immunologic dysfunction accounts for many of the clinically associated phenomenon such as @entity1 and second @entity0 . Much of this dysfunction has been attributed to poor B-cell function. Functional impairment of the T-cell component is currently being elucidated. In the investigation of B cells. The associated immunologic dysfunction accounts for many of the clinically associated phenomenon such as @entity1 and second @entity0 . Much of this dysfunction has been attributed to poor B-cell function. Functional impairment of the T-cell component is currently being elucidated. In the investigation of B cells. The associated immunologic dysfunction accounts for many of the clinically associated phenomenon such as @entity1 and second @entity0 . Much of this dysfunction has been attributed to poor B-cell function. Functional impairment of the T-cell component is currently being elucidated. In the investigation of B cells. The associated immunologic dysfunction accounts for many of the clinically associated phenomenon such as @entity1 and second @entity0 . Much of this dysfunction has been attributed to poor B-cell function. Functional impairment of the T-cell component is currently being elucidated. In the investigations reported herein, we further demonstrate the @entity4 of @entity2 by measuring proliferation and immunoglobulin synthesis in response to mitogens. Stimulation of various cell fractions indicates that in certain cases there is @entity3 , while others T function appears intact. In 2 of 4 cases tested there was augmentation of ig synthesis when the @entity2 cells were cocultured with thymic epithelium. The implications of such in vitro modulation are discussed.

title: Thymic dysfunction in XXXX .

answer: @entity2


abstract: PURPOSE: The concomitant use of @entity1 (TA) at the completion of pars plana vitrectomy for the treatment of epiretinal membrane may speed up the anatomical and functional outcomes of surgery. We report the outcome of @entity0 undergoing small-gauge vitrectomy for @entity2 with or without adjuvant TA therapy. DESIGN: This is a retrospective, single-center case series. METHODS: We included 75 eyes of 75 individual @entity0 . Twenty-six @entity0 (group A) had an adjuvant TA injection during surgery, whereas 49 @entity0 (group B) were not injected. We assessed the @entity0 for change in visual acuity (VA) and central macular thickness before and after surgery. RESULTS: Group A had a mean logarithm of the minimum angle of resolution VA of 0.63    0.33 and 0.51    0.31 preoperatively and 3 months after surgery, respectively. Group B had a mean logarithm of the minimum angle of resolution VA of 0.47    0.17 and 0.36    0.17 preoperatively and 3 months after surgery, respectively. No significant difference was found between the groups in change of VA. The mean central macular thickness for groups A and B @entity0 before surgery was 474.12    120  m and 445    85  m, decreasing to 369    70  m and 386    60  m at the final visit, respectively. The difference in macular thickness reduction between the groups was statistically significant. CONCLUSIONS: Anatomical and functional improvement was found in both groups after surgery. Macular thickness was further reduced in the group of @entity0 treated with adjuvant TA.

title: Role of Concomitant XXXX Injection in Small-Gauge Vitrectomy for Idiopathic @entity2 .

answer: @entity1


abstract: PURPOSE: The concomitant use of @entity1 (TA) at the completion of pars plana vitrectomy for the treatment of epiretinal membrane may speed up the anatomical and functional outcomes of surgery. We report the outcome of @entity0 undergoing small-gauge vitrectomy for @entity2 with or without adjuvant TA therapy. DESIGN: This is a retrospective, single-center case series. METHODS: We included 75 eyes of 75 individual @entity0 . Twenty-six @entity0 (group A) had an adjuvant TA injection during surgery, whereas 49 @entity0 (group B) were not injected. We assessed the @entity0 for change in visual acuity (VA) and central macular thickness before and after surgery. RESULTS: Group A had a mean logarithm of the minimum angle of resolution VA of 0.63    0.33 and 0.51    0.31 preoperatively and 3 months after surgery, respectively. Group B had a mean logarithm of the minimum angle of resolution VA of 0.47    0.17 and 0.36    0.17 preoperatively and 3 months after surgery, respectively. No significant difference was found between the groups in change of VA. The mean central macular thickness for groups A and B @entity0 before surgery was 474.12    120  m and 445    85  m, decreasing to 369    70  m and 386    60  m at the final visit, respectively. The difference in macular thickness reduction between the groups was statistically significant. CONCLUSIONS: Anatomical and functional improvement was found in both groups after surgery. Macular thickness was further reduced in the group of @entity0 treated with adjuvant TA.

title: Role of Concomitant @entity1 Injection in Small-Gauge Vitrectomy for Idiopathic XXXX .

answer: @entity2


abstract: AIM: To determine the number, distribution and cost of hospital admissions for @entity1 ( @entity1 ) in New Zealand. METHODS: National @entity0 -level routine data on admissions with a principal diagnosis of @entity1 (mostly ICD-10- AN J440 and J441) were obtained for the period July 1st 2008 to June 30th 2013. Admissions with length of stay (LOS) = 90 days were excluded. RESULTS: There were 61,516 admissions in 5 years. Admission rates and budget impact (in 2012/13 dollar values) were stable but the average length of stay (ALOS) declined from 5.09 to 4.37 days. In FY2012/13 the admission rate was 2.82 per 1000 population, with age standardised rate (ASR) 4.4- and 3.6-fold higher for Maori and Pacific @entity0 respectively than for European/others. For age = 15 years the ASR was 2.55 per 1000. Admission rates were higher for @entity0 than @entity0 and increased steeply with age and socioeconomic deprivation (NZDep06). The mean age at discharge was lower for Maori and Pacific @entity0 than for European/Others (63.4, 67.1 and 72.3 years). The mean 30-day readmission rate was 6.7%. The average LOS increased with age and was shorter for Maori (3.6 days) and Pacific @entity0 (3.5 days) than for European/Others (4.7 days). Admission rates varied widely across District Health Boards, and were higher in rural than urban regions. The estimated cost of admissions in FY2012/13 was  NZ59.6m. CONCLUSIONS: Hospital admissions for @entity1 are costly and are over-represented in high risk groups including rural, elderly, socioeconomically deprived and Maori and Pacific @entity0 . Effective interventions that are targeted to high risk groups are required to improve equity and reduce the burden of @entity1 .

title: Hospital admissions for XXXX in New Zealand.

answer: @entity1


abstract: In 65 @entity1 @entity0 aged 18 to 59 years maximal expiratory flow-volume curves were performed. The measurements were done with a pneumotachograph in connection with a self-developed two-channel FM modulator, a stereo tape recorder, and a X-Y recorder. We examined 53 @entity0 in clinical remission and 12 @entity0 during an attack period. The greatest sensitivity of the tested flow-volume data had @entity2 50/FVC pred. and the time constant of the terminal portion of the curve. @entity2 50/ @entity2 75 and V2/V1 were about equally sensitive for detecting ventilatory inhomogeneities. The attack group most differed from the remission groups in FVC % pred., @entity2 50/FVC pred. and the other flow rates. The flow-volume curve is a valuable method to assess obstruction and ventilatory inhomogeneity in @entity1 @entity0 . It has a greater sensitivity than conventional spirometry.

title: [Results of the flow-volume curve in XXXX with bronchial asthma (author's transl)].

answer: @entity0


abstract: Portulaca oleracea L. is an annual plant widely distributed from the temperate to the tropical zones. POL-P3b, a polysaccharide fraction purified from Portulaca oleracea L., is able to enhance immunity and inhibit @entity0 formation. Induction of antitumor immunity by @entity0 fusion cells can be modulated by their activation status. Mature dendritic cells are significantly better than immature dendritic cells at cytotoxic T-lymphocyte induction. In this study, we analyzed the effects of POL-P3b on the maturation and function of @entity1 bone-marrow-derived dendritic cells (DCs) and relevant mechanisms. The phenotypic maturation of DCs was confirmed by flow cytometry. We found that POL-P3b upregulated the expression of @entity5 , @entity6 , @entity7 , and major histocompatibility complex class II molecules on DCs, stimulated production of more interleukin (IL)-12, @entity0 @entity2 factor-a, and less @entity3 . Also, DCs pulsed POL-P3b and freeze-thaw antigen increased DCs-driven T cells' proliferation and promoted U14 cells' apoptosis. Furthermore, the expression of @entity4 was significantly increased on DCs treated by POL-P3b. These results suggested that POL-P3b may induce DCs maturation through @entity4 . Taken together, our results may have important implications for the molecular mechanisms of immunopotentiation of POL-P3b, and provide direct evidence to suggest that POL-P3b should be considered as a potent adjuvant nutrient supplement for DC-based vaccines.

title: Effects of Portulaca oleracea L. Polysaccharides on Phenotypic and Functional Maturation of XXXX Bone Marrow Derived Dendritic Cells.

answer: @entity1


abstract: BACKGROUND: We sought to evaluate the potential enhanced fibrinolytic and antiplatelet activity of @entity8 (DE) due to decreased @entity4 levels in @entity0 with @entity2 or transient @entity1 attack and @entity5 ( @entity5 ). METHODS: Consecutive @entity0 with @entity3 and @entity5 that were treated with DE in a tertiary university hospital. Fibrinolysis and platelet function were assessed by thromboelastometry (ROTEM) and platelet function analyzer (PFA)-100, respectively, before and after treatment with DE. Conventional coagulation tests, endogenous @entity4 potential (ETP) and hemoclot @entity4 inhibitors (HTI), were also performed in order to detect any possible correlation between @entity7 plasma levels, its anticoagulant activity and the intensity of @entity6 or fibrinolysis. RESULTS: A total of nineteen @entity0 fulfilled our inclusion criteria (mean age 62.3  7.2years; 47% males; median CHADS2-score: 3; interquartile range: 2-4). DE treatment was associated with a significant reduction of the lysis index (LI60) at 60min (p=0.036), and prolongation of the PFA-100 CEPI closure time (p=0.024). After @entity7 treatment, abnormal PFA-100 results were obtained in two @entity0 (11%, 95% CI: 2%-33%). DE levels (determined by HTI) were strongly inversely correlated (rho=-0.85; p<0.001) with the area under the curve (AUC) values in ETP assay.   o association was found between HTI and PFA-100 CEPI CT (p=0.64), or LI60 measurements (p=0.60). CONCLUSIONS: Our findings indicate that DE might affect platelet function and fibrinolysis and highlight the potential role of ETP as an alternative option in DE monitoring. The intensity and clinical relevance of DE antiplatelet and fibrinolytic effects require further investigation.

title: Impact of XXXX on platelet function and fibrinolysis.

answer: @entity7


abstract: The current treatment for @entity5 ( @entity5 ) with @entity2 manifestation is long-term anticoagulation. @entity6 antagonists (VKA) are usually the agents of choice. However, VKA limitations, such as unpredictable anticoagulation effects due to interaction with diet and other drugs, require regular monitoring. This may impact on @entity0 ' quality of life. Since the approval of new oral anticoagulants (NOAC) for non-valvular @entity3 and @entity4 prevention, much has been speculated about its use in @entity5 @entity0 . We report here a series of eight @entity5 @entity0 with failure of @entity2 prevention during @entity7 use. All @entity0 had @entity1 as the initial manifestation of @entity5 , and two of them also had arterial manifestations. Three @entity0 had triple antibody positivity. Five @entity0 developed arterial events during the treatment with @entity7 . Until the results of ongoing trials of @entity7 for @entity5 are presented, NOAC should not be recommended to @entity5 @entity0 . Our preliminary experience as well cases previously reported in the literature suggest that there is a high-risk group that is less protected with @entity7 , namely those with previous arterial @entity2 or triple positivity. VKA remains to be the mainstay treatment for @entity2 .

title: @entity2 events in patients with @entity5 treated with XXXX : a series of eight cases.

answer: @entity7


abstract: The current treatment for @entity5 ( @entity5 ) with @entity2 manifestation is long-term anticoagulation. @entity6 antagonists (VKA) are usually the agents of choice. However, VKA limitations, such as unpredictable anticoagulation effects due to interaction with diet and other drugs, require regular monitoring. This may impact on @entity0 ' quality of life. Since the approval of new oral anticoagulants (NOAC) for non-valvular @entity3 and @entity4 prevention, much has been speculated about its use in @entity5 @entity0 . We report here a series of eight @entity5 @entity0 with failure of @entity2 prevention during @entity7 use. All @entity0 had @entity1 as the initial manifestation of @entity5 , and two of them also had arterial manifestations. Three @entity0 had triple antibody positivity. Five @entity0 developed arterial events during the treatment with @entity7 . Until the results of ongoing trials of @entity7 for @entity5 are presented, NOAC should not be recommended to @entity5 @entity0 . Our preliminary experience as well cases previously reported in the literature suggest that there is a high-risk group that is less protected with @entity7 , namely those with previous arterial @entity2 or triple positivity. VKA remains to be the mainstay treatment for @entity2 .

title: @entity2 events in patients with XXXX treated with @entity7 : a series of eight cases.

answer: @entity5


abstract: The current treatment for @entity5 ( @entity5 ) with @entity2 manifestation is long-term anticoagulation. @entity6 antagonists (VKA) are usually the agents of choice. However, VKA limitations, such as unpredictable anticoagulation effects due to interaction with diet and other drugs, require regular monitoring. This may impact on @entity0 ' quality of life. Since the approval of new oral anticoagulants (NOAC) for non-valvular @entity3 and @entity4 prevention, much has been speculated about its use in @entity5 @entity0 . We report here a series of eight @entity5 @entity0 with failure of @entity2 prevention during @entity7 use. All @entity0 had @entity1 as the initial manifestation of @entity5 , and two of them also had arterial manifestations. Three @entity0 had triple antibody positivity. Five @entity0 developed arterial events during the treatment with @entity7 . Until the results of ongoing trials of @entity7 for @entity5 are presented, NOAC should not be recommended to @entity5 @entity0 . Our preliminary experience as well cases previously reported in the literature suggest that there is a high-risk group that is less protected with @entity7 , namely those with previous arterial @entity2 or triple positivity. VKA remains to be the mainstay treatment for @entity2 .

title: XXXX events in patients with @entity5 treated with @entity7 : a series of eight cases.

answer: @entity2


abstract: BACKGROUND: Inpatient treatment of chronic complex @entity5 can be necessary for @entity0 with a high symptomatic strain, mostly accompanied by a corresponding mental comorbidity, and/or for @entity0 that can only perceive their psychogenic suffering through somatization into @entity5 . METHODS: We report the results of 368 consecutively treated inpatients with chronic complex @entity5 . @entity0 ' audiometric data were collected, and at the beginning and end of treatment, the Mini-Tinnitus Questionnaire (Mini-TQ12; Hiller und Goebel) was completed, as was the German version of the Hospitality Anxiety and @entity4 Score (HADS). Effect sizes were calculated for both questionnaires. Mean treatment duration was 38.8 days (standard deviation, SD: 13.6 days). The main therapeutic elements were intensive disorder-specific neurotologic counselling and psychoeducation; improvement of hearing by fitting of hearing aids, complemented by an individualized hearing therapy; and intensive individual and group-based psychotherapy. RESULTS: In addition to @entity5 , 82.1% of the @entity0 had reduced hearing requiring rehabilitation with hearing aids. After hospitalization, a highly significant improvement in @entity5 could be demonstrated by the Mini-TQ12. Furthermore, a significant @entity4 and @entity2 components of HADS was also achieved, with high effect sizes of 1.6 to 2.2. No @entity3 to a medium- or low-range level was experienced by 8.9% of @entity0 . CONCLUSION: With corresponding symptomatic suffering, @entity1 neurotologic and psychosomatic alignment can achieve medium- to high-range therapeutic effects.

title: [Pre- and posttreatment results of an inpatient neurotologic and psychosomatic XXXX therapy].

answer: @entity5


abstract: BACKGROUND: @entity0 with @entity2 are often excluded from clinical trials based on age or a poor performance score. However, 70% of @entity2 is diagnosed in @entity0 over 65. Evaluation on the influence of age and comorbidity on survival and cause of @entity3 in a non-selected population. METHODS: Included were 621 consecutive @entity0 with @entity2 . An extensive chart review was performed for 392 @entity0 with @entity4 and 143 @entity0 with @entity1 . Analyses were performed separately for both groups. RESULTS: Median survival of @entity4 @entity0 was 5.13 years, 131 @entity0 (34.3%) died from @entity1 progression. Age and comorbidity were significant predictors for overall survival (P<0.001). Age was also a significant predictor of cause of @entity3 (P=0.001). In @entity1 @entity0 median survival was 4.67 years, 51 (35.7%) of @entity0 died from @entity1 progression. Neither age nor comorbidity was significant predictors of survival. Age was a significant predictor of cause of @entity3 (P<0.001). CONCLUSIONS: In @entity4 @entity0 age and comorbidity predict survival. This represents possible bias or a reduced survival benefit of treatment, and is an indication that @entity4 is not the prognosis defining illness in the majority of @entity0 . In @entity1 @entity0 neither age or comorbidity significantly impacted survival.

title: Impact of age and comorbidity on survival in XXXX .

answer: @entity2


abstract: BACKGROUND: The goal of surgery for @entity2 is cure. Unfortunately post-operative mortality occurs. This study aims to identify co-morbidity and causes of mortality in the post-operative period in relation to direct technical complications of surgery. METHODS: All consecutive @entity0 who underwent surgery for @entity2 were included. Co-morbidity was determined via the Charlson co-morbidity score. The post-operative course was studied and cause of @entity3 within 30 days was determined. @entity0 were divided in two groups: group 1 died within 30 days after surgery and group 2 survived for longer than 30 days. RESULTS: Twenty three out of 333 @entity0 (6.9%) with @entity4 and 6 out of 112 (5.3%) with @entity1 died in the post-operative period. @entity0 in group 1 were significantly older than @entity0 in group 2 (P<0.001). @entity0 in group 1 with @entity4 also significantly had more often a higher stage of @entity1 (P=0.03). The Charlson co-morbidity score for @entity0 with @entity4 in group 1 was mean 5.17 (SD 1.57, range, 1-8), and for @entity1 mean 4.83 (SD 2.32, range, 2-7). There was no difference in Charlson co-morbidity score when @entity0 from groups 1 and 2 were compared. In group 1, 13 (44%) died as a direct consequence of technical surgical complications. Sixteen @entity0 died due to complications because of pre-existing co-morbidity. CONCLUSIONS: Post-operative mortality very often is the direct result of pre-existing co-morbidity and not always the direct result of the surgical procedure.

title: Thirty days post-operative mortality after surgery for XXXX : a descriptive study.

answer: @entity2


abstract: Purpose/Aim of the Study. Subthreshold micropulse diode laser photocoagulation is an effective treatment for @entity2 . The molecular mechanisms underlying treatment success are poorly understood. Therefore, we investigated the effects of sublethal laser energy doses on a single layer of densely cultured @entity0 cells as a model of the @entity0 @entity1 ( @entity1 ). Materials and Methods. A single layer of densely cultured @entity0 @entity0 cells was perpendicularly irradiated with a micropulse diode laser. Nonirradiated cells served as controls. Sublethal laser energy was applied to form a photocoagulation-like area in the cultured cell layers. @entity3 expression was evaluated using quantitative polymerase chain reaction and immunocytochemistry. Results. Photocoagulation-like areas were successfully created in cultured @entity0 cell layers using sublethal laser energy with our laser irradiation system. @entity3 mRNA expression in cell layers was induced within 30   min of laser irradiation, peaking at 3   h after irradiation. This increase was dependent on the number of laser pulses. @entity3 upregulation was not observed in untreated cell layers. Immunostaining indicated that @entity3 expression occurred concentrically around laser irradiation sites and persisted for 24   h following irradiation. Conclusion. Sublethal photothermal stimulation with a micropulse laser may facilitate @entity3 expression in the @entity1 without inducing cellular damage.

title: Sublethal Photothermal Stimulation with a Micropulse Laser Induces Heat Shock Protein Expression in XXXX Cells.

answer: @entity0


abstract: The aim of this study was to discuss the effect of autogenic training (AT) on @entity0 with @entity2 ( @entity2 ) using salivary amylase, the skin temperature of the finger, subjective severity of symptoms, and psychological characteristics as measures. We assessed 20 @entity0 with @entity2 and 23 healthy controls before and after AT. Baseline levels of salivary amylase prior to an AT session were significantly higher in the @entity2 group than in the control group. However, this difference was not significant after AT. The skin temperature of the finger increased after AT in both the @entity2 and control groups. AT contributed to the improvement of somatic symptoms in @entity0 with @entity2 . Our results regarding psychological characteristics suggest that @entity1 are deeply involved in the pathology of @entity2 . Individuals with @entity2 exhibited elevated levels of sympathetic activity compared with healthy controls. Our data indicates that AT eased dysregulation of the autonomic nervous system in @entity0 with @entity2 . Thus, salivary amylase may be a useful index of change induced by AT in @entity0 with @entity2 .

title: Saliva amylase as a measure of sympathetic change elicited by autogenic training in XXXX with functional somatic syndromes.

answer: @entity0


abstract: Background and Aims. It is widely accepted that @entity1 ( @entity1 ) is independently associated with @entity5 . Similar to @entity1 , @entity2 ( @entity2 ) is a condition associated with @entity5 . However, to date, the impact of the simultaneous presence of @entity1 and @entity2 on the risk of @entity5 has not been extensively studied. The aim of this study was to evaluate the consequences of the coexistence of @entity1 and @entity2 on carotid @entity3 ( @entity3 ) and on inflammatory markers of @entity5 (such as interleukin- [IL-] 6 and pentraxin- [ @entity7 -] 3). Methods. The study design allowed us to define 4 groups: (1) controls (n = 30); (2) @entity1 @entity0 without @entity2 (n = 30); (3) @entity2 @entity0 without @entity1 (n = 30); (4) @entity0 with @entity1 and @entity2 (n = 30). In the morning after portable monitoring (between 7 am and 8 am), blood samples were collected, and carotid @entity3 was measured. Results. Carotid @entity3 , @entity4 , and @entity8 in @entity1 normotensive @entity0 and in non- @entity1 @entity2 subjects were significantly higher compared to control subjects; in addition, in @entity1 @entity2 @entity0 they were significantly increased compared to @entity1 normotensive, non- @entity1 @entity2 , or control subjects. Conclusions. @entity1 and @entity2 have an additive role in the progression of @entity6 and in blood levels of inflammatory markers for @entity5 , such as @entity4 and @entity8 .

title: Obstructive Sleep Apnea, XXXX , and Their Additive Effects on @entity5 .

answer: @entity2


abstract: Background and Aims. It is widely accepted that @entity1 ( @entity1 ) is independently associated with @entity5 . Similar to @entity1 , @entity2 ( @entity2 ) is a condition associated with @entity5 . However, to date, the impact of the simultaneous presence of @entity1 and @entity2 on the risk of @entity5 has not been extensively studied. The aim of this study was to evaluate the consequences of the coexistence of @entity1 and @entity2 on carotid @entity3 ( @entity3 ) and on inflammatory markers of @entity5 (such as interleukin- [IL-] 6 and pentraxin- [ @entity7 -] 3). Methods. The study design allowed us to define 4 groups: (1) controls (n = 30); (2) @entity1 @entity0 without @entity2 (n = 30); (3) @entity2 @entity0 without @entity1 (n = 30); (4) @entity0 with @entity1 and @entity2 (n = 30). In the morning after portable monitoring (between 7 am and 8 am), blood samples were collected, and carotid @entity3 was measured. Results. Carotid @entity3 , @entity4 , and @entity8 in @entity1 normotensive @entity0 and in non- @entity1 @entity2 subjects were significantly higher compared to control subjects; in addition, in @entity1 @entity2 @entity0 they were significantly increased compared to @entity1 normotensive, non- @entity1 @entity2 , or control subjects. Conclusions. @entity1 and @entity2 have an additive role in the progression of @entity6 and in blood levels of inflammatory markers for @entity5 , such as @entity4 and @entity8 .

title: Obstructive Sleep Apnea, @entity2 , and Their Additive Effects on XXXX .

answer: @entity5


abstract: INTRODUCTION: Evidence based psychotherapies (EBPs) remain underutilized. Models for @entity3 training and implementation that are cost-effective, minimally disruptive, and sufficiently flexible are needed. Internet-based technology is a promising platform, but questions remain about how this technology can address the barriers to implementation. We developed and examined the implementation of an online training for the Building Recovery by Improving Goals, Habits, and Thoughts (BRIGHT) intervention-a manualized, sixteen-session group @entity1 treatment for individuals with @entity2 ( @entity2 ). We explored the feasibility of replacing in- @entity0 BRIGHT training with a self-paced, online training. METHODS: A highly partnered and iterative process was followed to translate the written BRIGHT manual and associated didactic training materials into a media rich, interactive, and detailed (12-16h) online training. Subsequently, 8 volunteer counselors across 7 Veterans' Affairs SUD programs completed the training. Semi-structured interviews focused on the counselors' experiences and their plans for implementing BRIGHT groups. A template approach, using a mixture of deductive and inductive coding, was used for data analyses. FINDINGS: The most important barrier to completing training was a lack of protected time. Most counselors were not afforded protected time and reported a sometimes frustrating and fragmented training experience. Many used personal time at work and at home to complete the work. Facilitators to completing the training included positive reactions/attitudes towards the training modules, supervisor support, counselor dedication, and strong beliefs supporting providing services for @entity1 . Many counselors were also concerned about the feasibility of fitting 16 group sessions (2h each) into their program's clinical schedule, but many had devised potential solutions or "work-arounds" to accommodate or approximate the recommended treatment course (e.g., using lunch times, reducing some content/exercises). CONCLUSION: This work contributes to the literature on implementation of complex EBPs and addresses the strengths and limitations of web-based technologies in supporting the implementation of EBPs.

title: Training Substance Use Disorder Counselors in Cognitive Behavioral Therapy for XXXX : Development and Initial Exploration of an Online Training Program.

answer: @entity1


abstract: BACKGROUND: @entity2 ( @entity2 ) is an acute, potentially life-threatening @entity1 . There are limited population-based data on changes in the hospitalization rate and prognosis of @entity2 . OBJECTIVES: We sought to examine the proportion of @entity0 with @entity2 admitted to an intensive care unit (ICU), the prognosis of @entity2 , and time trends in @entity2 hospitalization rates in Denmark from 1995 through 2012. METHODS: We performed a population-based cohort study in Denmark from 1995 through 2012 (cumulative population, 7.1 million) using the Danish National @entity0 Registry and the Danish Civil Registration System. Outcomes included time trends in first-time @entity2 hospitalization rates, percentage admitted to an ICU, and 30-day mortality overall and stratified by year. RESULTS: We included 6,707 @entity0 with a first-time hospitalization for @entity2 during 103,747,997 @entity0 -years of observation time. The average @entity2 hospitalization rate was 64.6 (95% CI, 63.1-66.2) per 1,000,000 @entity0 -years. From 1995 to 2012, the annual @entity2 hospitalization rate increased more than 2-fold (rate ratio, 2.6; 95% CI, 2.2-3.0). However, the annual hospitalization rate in @entity0 increased 10-fold (rate ratio, 10.75; 95% CI, 5.59-20.67). Only 0.7% of @entity0 died within 30  days after admission (50 deaths), and most fatal @entity2 cases occurred among @entity0 aged 30  years or older. During the 2005-2012 period, 14.5% of @entity0 hospitalized with @entity2 were admitted to an ICU. CONCLUSION: The @entity2 hospitalization rate increased from 1995 to 2012; however, the 30-day mortality was less than 1%.

title: Hospitalization rates and prognosis of XXXX with anaphylactic shock in Denmark from 1995 through 2012.

answer: @entity0


abstract: UNASSIGNED: An investigation of gill monogeneans from the @entity3 @entity3 and the blue spotted tilapia @entity3 leucostictus (50 individuals per species) was done between the months of November 2014 to February 2015 in Lake Naivasha, Kenya. Standard parasitological procedures were used to examine fish gills for the presence of monogeneans. The observed monogeneans were collected, preliminarily identified using identification keys, quantified and fixed in 4  % @entity0 for morphological studies and absolute @entity1 for molecular studies. Four parasite species comprising of three species of the genus Cichlidogyrus and one species of the genus Scutogyrus were recovered. Cichlidogyrus sclerosus and Cichlidogyrus tilapiae infested both fish species but the C. sclerosus was most prevalent in O. leucostictus (Prevalence (P)   =   100  %, @entity2 ( @entity2 )   =   3.4) and C. tilapiae in @entity3 (P   =   8  %, @entity2   =   4). Cichlidogyrus tilapiae had a P   =   12  % and @entity2   =   5.0 and a P   =   6  % and @entity2   =   3.0 in @entity3 and O. leucostictus, respectively. Cichlidogyrus halli (P   =   4  %, @entity2   =   15.5) and Scutogyrus gravivaginus (P   =   2  %, @entity2   =   1.0) were only found in O. leucostictus. This is the first time that these monogeneans have been identified from Lake Naivasha, Kenya, presenting new geographical records. It was concluded that Ancyrocephalids (Cichilidogyrus spp.) dominated the two cichlid fish species in Lake Naivasha, Kenya.

title: Gill monogeneans of XXXX ) and @entity3 leucostictus (Trewavas, 1933) in Lake Naivasha, Kenya.

answer: @entity3


abstract: UNASSIGNED: An investigation of gill monogeneans from the @entity3 @entity3 and the blue spotted tilapia @entity3 leucostictus (50 individuals per species) was done between the months of November 2014 to February 2015 in Lake Naivasha, Kenya. Standard parasitological procedures were used to examine fish gills for the presence of monogeneans. The observed monogeneans were collected, preliminarily identified using identification keys, quantified and fixed in 4  % @entity0 for morphological studies and absolute @entity1 for molecular studies. Four parasite species comprising of three species of the genus Cichlidogyrus and one species of the genus Scutogyrus were recovered. Cichlidogyrus sclerosus and Cichlidogyrus tilapiae infested both fish species but the C. sclerosus was most prevalent in O. leucostictus (Prevalence (P)   =   100  %, @entity2 ( @entity2 )   =   3.4) and C. tilapiae in @entity3 (P   =   8  %, @entity2   =   4). Cichlidogyrus tilapiae had a P   =   12  % and @entity2   =   5.0 and a P   =   6  % and @entity2   =   3.0 in @entity3 and O. leucostictus, respectively. Cichlidogyrus halli (P   =   4  %, @entity2   =   15.5) and Scutogyrus gravivaginus (P   =   2  %, @entity2   =   1.0) were only found in O. leucostictus. This is the first time that these monogeneans have been identified from Lake Naivasha, Kenya, presenting new geographical records. It was concluded that Ancyrocephalids (Cichilidogyrus spp.) dominated the two cichlid fish species in Lake Naivasha, Kenya.

title: Gill monogeneans of @entity3 ) and XXXX leucostictus (Trewavas, 1933) in Lake Naivasha, Kenya.

answer: @entity3


abstract: The use of insulin pump in @entity1 is likely to increase with recent advances in technology. Although the evidence for the superiority of pumps over @entity3 ( @entity3 ) is inconsistent, data from accumulating uncontrolled studies indicate greater reductions in glycated haemoglobin in @entity0 switching to continuous subcutaneous insulin infusion (CSII) from @entity3 therapy. Due to the variability in insulin requirements and sensitivity to CSII pumps, hyperglycaemia in these @entity0 is managed by endocrinologists using individualised therapy. A panel of experts reviewed the existing guidelines and framed recommendations specific to the clinical practice in Indian conditions for use of CSII pumps in the management of hyperglycaemia. Selection of right @entity0 with basic education, motivation and learning skills are essential for successful implementation of CSII therapy with sophisticated programmes. Rapid acting insulin analogues with better pharmacokinetic and pharmacodynamic profile, physical and chemical stability and compatibility with most commercially available insulin pumps are preferred over regular insulin to achieve safe and stable glycaemic control. Further, educating pump users on proper use of CSII pumps, insulin dose adjustments, and handling of accessories are recommended in the current consensus guidelines. Practice of self-monitoring of blood @entity2 and glycated haemoglobin levels are essential to adjust insulin dosage for the management of @entity1 . Use of CSII pumps in special @entity0 populations should be carefully assessed and initiated by endocrinologist. The proposed guidelines can form a basis for use of CSII pumps in the management of hyperglycaemia in the Indian scenario.

title: Consensus evidence-based guidelines for use of insulin pump therapy in the management of XXXX as per Indian clinical practice.

answer: @entity1


abstract: BACKGROUND: Physical function and strength decline with age and lead to limited mobility and independence in older adults. Alterations in mitochondrial function are thought to underlie numerous age-related changes, including declining physical ability. Recent studies suggest that systemic changes in bioenergetic capacity may be reported by analyzing mitochondrial function in circulating cells. The objective of this study was to determine whether the bioenergetic capacity of peripheral blood mononuclear cells (PBMCs) is related to differences in physical function among older, overweight/ @entity1 , adults. To address this, we tested the hypothesis that greater PBMC respirometric capacity would be associated with better physical function, muscular strength, leg lean mass, and @entity2 . Furthermore, we tested whether the respirometric capacity of PBMCs is related to cellular composition and inflammatory status reported by @entity3 ( @entity3 ). METHODS: Fasted PBMC respiration (pmol/min/500,000 cells), expanded short physical performance battery (Ex-SPPB), peak knee extensor (KE) strength (Nm), grip strength (kg), leg lean mass (kg, via dual energy X-ray absorptiometry [DXA]), @entity2 (Nm/kg), and plasma @entity3 (pg/mL) were analyzed in 15 well-functioning, community-dwelling, sedentary overweight/ @entity1 older @entity0 (n=9) and @entity0 (n=6) aged 65 to 78 (mean 68.3  3.5years). Pearson and partial correlations were calculated to determine associations between PBMC respiration and these variables. RESULTS: Higher maximal respiration of PBMCs was associated with better Ex-SPPB (r=0.58, p=0.02), greater KE strength (r=0.60, p=0.02), greater grip strength (r=0.52, p=0.05) and lower @entity3 (r=-0.58, p=0.04). Higher spare respiratory capacity was associated with better Ex-SPPB (r=0.59, p=0.02), greater KE strength (r=0.60, p=0.02), greater grip strength (r=0.54, p=0.04), greater leg @entity2 (r=0.56, p=0.04), and lower @entity3 (r=-0.55, p=0.05). Monocyte and lymphocyte counts were not related to PBMC respiratory capacity. CONCLUSIONS: Our results indicate that respirometric profiles of readily obtainable blood cells are associated with physical function and strength. Future studies should be undertaken in order to determine whether blood-based bioenergetic profiling can provide an objective index of systemic mitochondrial health.

title: Blood-cell bioenergetics are associated with physical function and inflammation in overweight/ XXXX older adults.

answer: @entity1


abstract: BACKGROUND: Genetically determined @entity2 ( @entity2 ) is an intractable condition that involves severe impairment of mental abilities such as learning, reasoning and predicting the future. As of today, little is known about the placebo response in @entity0 with @entity2 . OBJECTIVE: To determine if placebo response exists in @entity0 with genetically determined @entity2 . DATA SOURCES AND STUDY SELECTION: We searched Medline/PubMed, EMBASE, CENTRAL and PsycINFO to find all placebo-controlled double-blind @entity3 ( @entity3 ) in @entity0 with genetically determined @entity2 , published up to April 2013, focusing on core @entity2 symptoms. DATA EXTRACTION AND SYNTHESIS: Two investigators extracted outcome data independently. MAIN OUTCOMES AND MEASURES: Bias-corrected standardized mean difference (Hedge's g) was computed for each outcome measure, using the Comprehensive Meta-Analysis software. A priori defined @entity0 sub-groups were analyzed using a mixed-effect model. The relationship between pre-defined continuous variable moderators (age, IQ, year of publication and trial duration) and effect size was analyzed using meta-regression. RESULTS: Twenty-two placebo-controlled double-blind @entity3 met the inclusion criteria (n = 721, mean age = 17.1 years, 62% @entity0 , mean trial duration = 35 weeks). There was a significant overall placebo response from pre- to post-treatment in @entity0 with @entity2 (g = 0.468, p = 0.002), both for "subjective outcomes" (a third- @entity0 's evaluation of the @entity0 ) (g = 0.563, p = 0.022) and "objective outcomes" (direct evaluation of the @entity0 's abilities) (g = 0.434, p = 0.036). Individuals with higher IQ had higher response to placebo (p = 0.02) and no placebo response was observed in @entity2 @entity0 with comorbid @entity1 . A significant effect of age (p = 0.02) was found, indicating higher placebo responses in treatment of younger @entity0 . CONCLUSIONS AND RELEVANCE: Results suggest that @entity0 with genetically determined @entity2 improve in the placebo arm of @entity3 . Several mechanisms may contribute to placebo effects in @entity2 , including expectancy, implicit learning and "placebo-by-proxy" induced by clinicians/family members. As the condition is refractory, there is little risk that improvements are explained by spontaneous remission. While new avenues for treatment of genetically determined @entity2 are emerging, our results demonstrate how contextual factors can affect clinical outcomes and emphasize the importance of being vigilant on the role of placebos when testing novel treatments in @entity2 .

title: Placebo Responses in Genetically Determined XXXX : A Meta-Analysis.

answer: @entity2


abstract: PURPOSE: Studies have suggested an association between the use of regional paravertebral or epidural anesthesia and a reduction in @entity2 recurrence following @entity0 surgery. To examine this relationship we performed a retrospective case-control study of @entity1 undergoing @entity0 surgery receiving regional, regional and general, or general anesthesia. METHODS: A retrospective chart review was performed of @entity1 undergoing surgery for stage 0 to III @entity0 . @entity1 identified as receiving regional anesthesia were then matched for age, stage, @entity4 ( @entity4 ) status, @entity5 status, and @entity3 expression with @entity1 who received no regional anesthesia. Univariate (Pearson's   2 test and odds ratio) and multivariate logistic analyses with backward stepwise regression were performed to determine factors associated with @entity2 recurrence. RESULTS: Between 1998 and 2007, 816 @entity1 underwent surgery for stage 0-III @entity0 at our institution. Forty-five @entity1 developed @entity2 . Univariate analysis showed the use of regional anesthesia trended towards reduced @entity2 recurrence, but it did not achieve statistical significance (p = 0.06). Higher recurrence rates were associated with @entity4 positive status (p = 0.003) and higher @entity2 stage (p < 0.0001). Age and @entity3 status were not associated with increased @entity2 recurrence (both p > 0.11). Multivariate analysis confirmed @entity4 status and stage as independently influential (p = 0.002 and p < 0.0001 respectively). CONCLUSION: Although we found a trend towards reduced @entity0 recurrence with the use of regional anesthesia, univariate analysis did not reach statistical significance.

title: XXXX recurrence in @entity1 receiving epidural and paravertebral anesthesia: a retrospective, case-control study.

answer: @entity0


abstract: PURPOSE: Studies have suggested an association between the use of regional paravertebral or epidural anesthesia and a reduction in @entity2 recurrence following @entity0 surgery. To examine this relationship we performed a retrospective case-control study of @entity1 undergoing @entity0 surgery receiving regional, regional and general, or general anesthesia. METHODS: A retrospective chart review was performed of @entity1 undergoing surgery for stage 0 to III @entity0 . @entity1 identified as receiving regional anesthesia were then matched for age, stage, @entity4 ( @entity4 ) status, @entity5 status, and @entity3 expression with @entity1 who received no regional anesthesia. Univariate (Pearson's   2 test and odds ratio) and multivariate logistic analyses with backward stepwise regression were performed to determine factors associated with @entity2 recurrence. RESULTS: Between 1998 and 2007, 816 @entity1 underwent surgery for stage 0-III @entity0 at our institution. Forty-five @entity1 developed @entity2 . Univariate analysis showed the use of regional anesthesia trended towards reduced @entity2 recurrence, but it did not achieve statistical significance (p = 0.06). Higher recurrence rates were associated with @entity4 positive status (p = 0.003) and higher @entity2 stage (p < 0.0001). Age and @entity3 status were not associated with increased @entity2 recurrence (both p > 0.11). Multivariate analysis confirmed @entity4 status and stage as independently influential (p = 0.002 and p < 0.0001 respectively). CONCLUSION: Although we found a trend towards reduced @entity0 recurrence with the use of regional anesthesia, univariate analysis did not reach statistical significance.

title: @entity0 recurrence in XXXX receiving epidural and paravertebral anesthesia: a retrospective, case-control study.

answer: @entity1


abstract: UNASSIGNED: Recently, great progress has been achieved in the treatment of @entity4 ( @entity4 ). However, some @entity0 , particularly older @entity0 with comorbidities or with relapsed/ @entity5 , still have limited therapeutic options. There is an urgent need to discover less toxic and more effective drugs for @entity4 @entity0 . Applying new modalities or substances that are widely used for the treatment of other diseases has been reported to improve results in @entity4 treatment. This study aimed to assess the non-chemotherapeutic drug @entity6 for its potential to destroy @entity5 cells. Leukemic cells, obtained from the peripheral blood and bone marrow of 23 @entity4 @entity0 , were cultured in the presence of @entity6 and its combination with the purine @entity10 analogs @entity7 and @entity11 and @entity12 . After 24  h of incubation, the rate of apoptosis indicated by active @entity3 expression, and @entity2 indicated by forward light scatter and light scatter analysis, was assessed by flow cytometry. We also measured expression of apoptosis-regulating proteins of BCL family and active @entity9 and active @entity8 expressions in @entity5 cells. @entity6 had a caspase-dependent pro-apoptotic and cytotoxic effect on @entity5 cells in a @entity1 -specific manner. The mechanisms of its action appear to be complex and should be precisely established; however, induction of apoptosis involving both mitochondrial and receptor cascades appears to be most probable. @entity6 showed a synergic effect with @entity11 , an additive effect with @entity7 , and an infra-additive effect with @entity12 . The rate of @entity6 -induced apoptosis and @entity2 did not differ between @entity0 with better and worse prognostic markers. Our results indicate that @entity6 may be a potential therapeutic agent for @entity4 @entity0 alone and in combination with @entity13 analogs.

title: @entity6 induces apoptosis and @entity2 of XXXX cells alone and in combination with purine nucleoside analogs in @entity4 .

answer: @entity5


abstract: UNASSIGNED: Recently, great progress has been achieved in the treatment of @entity4 ( @entity4 ). However, some @entity0 , particularly older @entity0 with comorbidities or with relapsed/ @entity5 , still have limited therapeutic options. There is an urgent need to discover less toxic and more effective drugs for @entity4 @entity0 . Applying new modalities or substances that are widely used for the treatment of other diseases has been reported to improve results in @entity4 treatment. This study aimed to assess the non-chemotherapeutic drug @entity6 for its potential to destroy @entity5 cells. Leukemic cells, obtained from the peripheral blood and bone marrow of 23 @entity4 @entity0 , were cultured in the presence of @entity6 and its combination with the purine @entity10 analogs @entity7 and @entity11 and @entity12 . After 24  h of incubation, the rate of apoptosis indicated by active @entity3 expression, and @entity2 indicated by forward light scatter and light scatter analysis, was assessed by flow cytometry. We also measured expression of apoptosis-regulating proteins of BCL family and active @entity9 and active @entity8 expressions in @entity5 cells. @entity6 had a caspase-dependent pro-apoptotic and cytotoxic effect on @entity5 cells in a @entity1 -specific manner. The mechanisms of its action appear to be complex and should be precisely established; however, induction of apoptosis involving both mitochondrial and receptor cascades appears to be most probable. @entity6 showed a synergic effect with @entity11 , an additive effect with @entity7 , and an infra-additive effect with @entity12 . The rate of @entity6 -induced apoptosis and @entity2 did not differ between @entity0 with better and worse prognostic markers. Our results indicate that @entity6 may be a potential therapeutic agent for @entity4 @entity0 alone and in combination with @entity13 analogs.

title: @entity6 induces apoptosis and XXXX of @entity5 cells alone and in combination with purine nucleoside analogs in @entity4 .

answer: @entity2


abstract: UNASSIGNED: Recently, great progress has been achieved in the treatment of @entity4 ( @entity4 ). However, some @entity0 , particularly older @entity0 with comorbidities or with relapsed/ @entity5 , still have limited therapeutic options. There is an urgent need to discover less toxic and more effective drugs for @entity4 @entity0 . Applying new modalities or substances that are widely used for the treatment of other diseases has been reported to improve results in @entity4 treatment. This study aimed to assess the non-chemotherapeutic drug @entity6 for its potential to destroy @entity5 cells. Leukemic cells, obtained from the peripheral blood and bone marrow of 23 @entity4 @entity0 , were cultured in the presence of @entity6 and its combination with the purine @entity10 analogs @entity7 and @entity11 and @entity12 . After 24  h of incubation, the rate of apoptosis indicated by active @entity3 expression, and @entity2 indicated by forward light scatter and light scatter analysis, was assessed by flow cytometry. We also measured expression of apoptosis-regulating proteins of BCL family and active @entity9 and active @entity8 expressions in @entity5 cells. @entity6 had a caspase-dependent pro-apoptotic and cytotoxic effect on @entity5 cells in a @entity1 -specific manner. The mechanisms of its action appear to be complex and should be precisely established; however, induction of apoptosis involving both mitochondrial and receptor cascades appears to be most probable. @entity6 showed a synergic effect with @entity11 , an additive effect with @entity7 , and an infra-additive effect with @entity12 . The rate of @entity6 -induced apoptosis and @entity2 did not differ between @entity0 with better and worse prognostic markers. Our results indicate that @entity6 may be a potential therapeutic agent for @entity4 @entity0 alone and in combination with @entity13 analogs.

title: @entity6 induces apoptosis and @entity2 of @entity5 cells alone and in combination with purine nucleoside analogs in XXXX .

answer: @entity4


abstract: UNASSIGNED: Recently, great progress has been achieved in the treatment of @entity4 ( @entity4 ). However, some @entity0 , particularly older @entity0 with comorbidities or with relapsed/ @entity5 , still have limited therapeutic options. There is an urgent need to discover less toxic and more effective drugs for @entity4 @entity0 . Applying new modalities or substances that are widely used for the treatment of other diseases has been reported to improve results in @entity4 treatment. This study aimed to assess the non-chemotherapeutic drug @entity6 for its potential to destroy @entity5 cells. Leukemic cells, obtained from the peripheral blood and bone marrow of 23 @entity4 @entity0 , were cultured in the presence of @entity6 and its combination with the purine @entity10 analogs @entity7 and @entity11 and @entity12 . After 24  h of incubation, the rate of apoptosis indicated by active @entity3 expression, and @entity2 indicated by forward light scatter and light scatter analysis, was assessed by flow cytometry. We also measured expression of apoptosis-regulating proteins of BCL family and active @entity9 and active @entity8 expressions in @entity5 cells. @entity6 had a caspase-dependent pro-apoptotic and cytotoxic effect on @entity5 cells in a @entity1 -specific manner. The mechanisms of its action appear to be complex and should be precisely established; however, induction of apoptosis involving both mitochondrial and receptor cascades appears to be most probable. @entity6 showed a synergic effect with @entity11 , an additive effect with @entity7 , and an infra-additive effect with @entity12 . The rate of @entity6 -induced apoptosis and @entity2 did not differ between @entity0 with better and worse prognostic markers. Our results indicate that @entity6 may be a potential therapeutic agent for @entity4 @entity0 alone and in combination with @entity13 analogs.

title: XXXX induces apoptosis and @entity2 of @entity5 cells alone and in combination with purine nucleoside analogs in @entity4 .

answer: @entity6


abstract: A model system capable of providing clinically relevant analgesic doses with minimal @entity2 has been elusive in laboratory animal medicine. Our laboratory has developed an @entity3 system that effectively discriminates between nonnoxious and noxious thermal stimuli in @entity1 and @entity0 . Male and female @entity1 (Crl:SD) and @entity0 (Crl: @entity7 -HR(hr)) were trained to perform a task (placing their face through an opening and having their cheeks stay in contact with thermodes) to receive a reward (a solution of sweetened condensed milk). Currently accepted doses of @entity6 were tested by using a crossover design. @entity3 was induced in both species by sensitizing the depilated skin over both cheeks with @entity5 cream or by creating a @entity4 ( @entity1 only) and then allowing the animals to contact a temperature-regulated thermode while obtaining a reward. Optimal antinociceptive doses included 0.05 and 0.1 mg/kg in male @entity0 but only 0.05 mg/kg in female @entity0 . In rats, optimal antinociceptive doses included 0.03 and 0.05 mg/kg for male @entity1 but only 0.03 mg/kg for female @entity1 . The 2 pain-induction models in @entity1 ( @entity5 cream and @entity4 ) did not differ. Our @entity3 assay can determine clinically relevant analgesic doses for rodents in a preclinical assay. The automated, investigator-independent nature of the assay, in conjunction with its high sensitivity, makes this method an improvement over traditional noninvasive methods, providing better data for developing optimal analgesic recommendations for @entity1 and @entity0 .

title: Assessment of an Orofacial Operant XXXX Assay as a Preclinical Tool for Evaluating Analgesic Efficacy in Rodents.

answer: @entity3


abstract: As a nitrogen-fixing bacterium, @entity1 can establish a symbiotic relationship with the @entity0 plant ( @entity0 ). To be a successful symbiont, @entity2 must deal with plant defense responses, such as an oxidative burst. Our previous functional genomics study showed that carQ (bll1028) encoding extracytoplasmic function (ECF) sigma factor was highly expressed (107.8-fold induction) under oxidative stress. Little is known about the underlying mechanisms of how CarQ responds to oxidative stress. In this study, a carQ knock-out mutant was constructed using site-specific mutagenesis to identify the role of carQ in the oxidative response of @entity2 . The carQ mutant showed a longer generation time than the wild type and exhibited significantly decreased survival at 10 mM H(2)O(2) for 10 min of exposure. Surprisingly, there was no significant difference in expression of oxidative stress-responsive genes such as katG and sod between the wild type and carQ mutant. The mutant also showed a significant increase in susceptibility to H(2)O(2) compared to the wild type in the zone inhibition assay. Nodulation phenotypes of the carQ mutant were distinguishable compared to those of the wild type, including lower numbers of nodules, decreased nodule dry weight, decreased plant dry weight, and a lower nitrogen fixation capability. Moreover, desiccation of mutant cells also resulted in significantly lower percent of survival in both early (after 4 h) and late (after 24 h) desiccation periods. Taken together, this information will provide an insight into the role of the ECF sigma factor in @entity2 to deal with a plant-derived oxidative burst.

title: Role of the extracytoplasmic function sigma factor CarQ in oxidative response of XXXX .

answer: @entity1


abstract: UNASSIGNED: The non-coding microRNAs (miRNAs) have tissue- and disease-specific expression patterns. Dysregulation of miRNAs has been associated with initiation and progression of oncogenesis in @entity1 . The abnormal expression of @entity4 phosphatases detected in a number of @entity2 implies that their dysregulation is involved in malignant transformation. Using miRNA target prediction software, we found that @entity6 could target the 3'UTR sequence of @entity4 . To shed light on their roles of @entity6 in @entity0 , the expression of @entity6 was examined by real-time RT-PCR in @entity0 and normal tissues. @entity6 is significantly downregulated in @entity0 . @entity6 re-expression suppressed cell growth, cell cycle, migration, and invasion in @entity0 ( @entity0 ) cell line MDA-MB231. Luciferase expression from a reporter vector containing the @entity4 -3'UTR was decreased when this construct was transfected with @entity6 . The over-expression of @entity6 suppressed the endogenous @entity4 protein level in @entity0 cells. For the first time, we demonstrate that miRNA-211 is a direct negative regulator of @entity4 expression in @entity0 cells, alters other related target proteins @entity5 and @entity3 , and then inhibits @entity0 cells growth, migration, and invasion and lead G2/M arrest. The transcriptional loss of @entity6 and the resultant increase in @entity4 expression facilitate increased genomic instability at an early stage of @entity2 development.

title: MicroRNA-211, a direct negative regulator of XXXX expression, inhibits @entity0 cells' growth and migration.

answer: @entity4


abstract: UNASSIGNED: The non-coding microRNAs (miRNAs) have tissue- and disease-specific expression patterns. Dysregulation of miRNAs has been associated with initiation and progression of oncogenesis in @entity1 . The abnormal expression of @entity4 phosphatases detected in a number of @entity2 implies that their dysregulation is involved in malignant transformation. Using miRNA target prediction software, we found that @entity6 could target the 3'UTR sequence of @entity4 . To shed light on their roles of @entity6 in @entity0 , the expression of @entity6 was examined by real-time RT-PCR in @entity0 and normal tissues. @entity6 is significantly downregulated in @entity0 . @entity6 re-expression suppressed cell growth, cell cycle, migration, and invasion in @entity0 ( @entity0 ) cell line MDA-MB231. Luciferase expression from a reporter vector containing the @entity4 -3'UTR was decreased when this construct was transfected with @entity6 . The over-expression of @entity6 suppressed the endogenous @entity4 protein level in @entity0 cells. For the first time, we demonstrate that miRNA-211 is a direct negative regulator of @entity4 expression in @entity0 cells, alters other related target proteins @entity5 and @entity3 , and then inhibits @entity0 cells growth, migration, and invasion and lead G2/M arrest. The transcriptional loss of @entity6 and the resultant increase in @entity4 expression facilitate increased genomic instability at an early stage of @entity2 development.

title: MicroRNA-211, a direct negative regulator of @entity4 expression, inhibits XXXX cells' growth and migration.

answer: @entity0


abstract: UNASSIGNED: @entity0 tissue @entity4 -related peptidases (KLK) are a group of 15 @entity3 proteases which have been investigated as potential @entity1 biomarkers. This study determined the prognostic significance of @entity5 and 15 expression levels in @entity2 specimens. Expression of @entity5 and @entity6 was assessed by immunohistochemistry staining on a tissue microarray constructed from 113 gastrectomy specimens from @entity0 with @entity2 . To minimize inter-observer variability, expression levels were quantified using an automated algorithm. Epithelial and stromal staining were assessed separately. Both @entity5 and @entity6 were expressed in @entity2 . There was no significant correlation between either @entity5 or @entity6 expression and the presence of lymph node metastases or Lauren classification (intestinal vs. diffuse). Higher levels of @entity5 expression in @entity2 were associated with significantly worse overall survival (p   =   0.008), and a multivariate analysis showed that it had prognostic value independent of @entity1 stage and differentiation (p   =   0.004). Variations in @entity6 expression were not significantly associated with prognosis. @entity5 shows promise as a potential independent prognostic marker for @entity2 .

title: Prognostic significance of @entity0 tissue XXXX -related peptidases 11 and 15 in @entity2 .

answer: @entity4


abstract: UNASSIGNED: @entity0 tissue @entity4 -related peptidases (KLK) are a group of 15 @entity3 proteases which have been investigated as potential @entity1 biomarkers. This study determined the prognostic significance of @entity5 and 15 expression levels in @entity2 specimens. Expression of @entity5 and @entity6 was assessed by immunohistochemistry staining on a tissue microarray constructed from 113 gastrectomy specimens from @entity0 with @entity2 . To minimize inter-observer variability, expression levels were quantified using an automated algorithm. Epithelial and stromal staining were assessed separately. Both @entity5 and @entity6 were expressed in @entity2 . There was no significant correlation between either @entity5 or @entity6 expression and the presence of lymph node metastases or Lauren classification (intestinal vs. diffuse). Higher levels of @entity5 expression in @entity2 were associated with significantly worse overall survival (p   =   0.008), and a multivariate analysis showed that it had prognostic value independent of @entity1 stage and differentiation (p   =   0.004). Variations in @entity6 expression were not significantly associated with prognosis. @entity5 shows promise as a potential independent prognostic marker for @entity2 .

title: Prognostic significance of @entity0 tissue @entity4 -related peptidases 11 and 15 in XXXX .

answer: @entity2


abstract: UNASSIGNED: @entity0 tissue @entity4 -related peptidases (KLK) are a group of 15 @entity3 proteases which have been investigated as potential @entity1 biomarkers. This study determined the prognostic significance of @entity5 and 15 expression levels in @entity2 specimens. Expression of @entity5 and @entity6 was assessed by immunohistochemistry staining on a tissue microarray constructed from 113 gastrectomy specimens from @entity0 with @entity2 . To minimize inter-observer variability, expression levels were quantified using an automated algorithm. Epithelial and stromal staining were assessed separately. Both @entity5 and @entity6 were expressed in @entity2 . There was no significant correlation between either @entity5 or @entity6 expression and the presence of lymph node metastases or Lauren classification (intestinal vs. diffuse). Higher levels of @entity5 expression in @entity2 were associated with significantly worse overall survival (p   =   0.008), and a multivariate analysis showed that it had prognostic value independent of @entity1 stage and differentiation (p   =   0.004). Variations in @entity6 expression were not significantly associated with prognosis. @entity5 shows promise as a potential independent prognostic marker for @entity2 .

title: Prognostic significance of XXXX tissue @entity4 -related peptidases 11 and 15 in @entity2 .

answer: @entity0


abstract: PURPOSE: To appraise the role of stereotactic body radiation therapy (SBRT) in @entity0 with lung metastasis from primary soft tissue @entity3 . METHODS: Twenty-eight @entity0 (51 lesions) were analysed. All @entity0 were in good performance status (1-2 eastern cooperative oncology group (ECOG)), unsuitable for surgical resection, with controlled primary @entity1 and the number of lung metastases was    4. In a risk adaptive scheme, the dose prescription was: 30Gy/1fr, 60Gy/3fr, 60Gy/8fr and 48Gy/4fr. Treatments were performed with Volumetric Modulated Arc Therapy. Clinical outcome was evaluated by thoracic and abdominal computed tomography (CT) scan before SBRT and than every 3months. @entity2 was evaluated with Common Terminology Criteria for Adverse Events (CTCAE) scale version 4.0. RESULTS: @entity6 (36%) and @entity5 (25%) were the most common histologies. Five @entity0 (18%) initially presented with @entity4 , whereas 23 (82%) developed them at a median time of 51months (range 11-311months) from the initial diagnosis. The median follow-up time from initial diagnosis was 65months (5-139months) and from SBRT was 21months (2-80months). No severe @entity2 (grades III-IV) was recorded and no @entity0 required hospitalisation. The actuarial 5-years local control rate (from SBRT treatment) was 96%. Overall survival at 2 and 5years was 96.2% and 60.5%, respectively. At last follow-up 15 @entity0 (54%) were alive. All other died because of distant progression. CONCLUSIONS: SBRT provides excellent local control of @entity4 from soft tissue @entity3 (STS) and may improve survival in selected @entity0 . SBRT should be considered for all @entity0 with @entity4 ( @entity4 ) and evaluated in a multidisciplinary team.

title: Stereotactic body radiation therapy for lung metastases from soft tissue XXXX .

answer: @entity3